Amylyx
2014
FOUNDED
PRIVATE
STATUS
1-10
EMPLOYEES
Early Stage VC
LATEST DEAL TYPE
$14.8M
LATEST DEAL AMOUNT
6
INVESTORS
Description
Developer of a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases designed to target the neuroinflammation and nerve cell death that characterize these disorders. The company's therapeutics are a combination of existing compounds that have synergistic effects in preventing nerve cell death and neurotoxic inflammation in multiple preclinical models, enabling patients suffering from Alzheimer's disease and other neuroinflammation diseases to begin treatment more quickly, resulting in a higher likelihood of a successful treatment.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Primary Office
- 210 Broadway
- Suite 201
- Cambridge, MA 02139
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Amylyx’s full profile, request a free trial.
Amylyx Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC | 20-Nov-2018 | $14.8M | 000.00 | Completed | Generating Revenue | |
| 3. Early Stage VC (Series A) | 22-Aug-2016 | 000 | 00.00 | 0000 | Completed | Generating Revenue |
| 2. Grant | 20-Jul-2016 | $3.56M | $1.3M | Completed | Generating Revenue | |
| 1. Early Stage VC | $1.3M | $1.3M | Completed | Generating Revenue |
Amylyx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Amylyx Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| ALS Investment Fund | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Henri Termeer | Angel (individual) | Minority | 000 0000 | 000000 0 | ||
| Morningside Group | PE/Buyout | Minority | 000 0000 | 000000 0 | ||
| ALS Finding a Cure Foundation | Limited Partner | Minority | 000 0000 | 000000 0 | ||
| Cure Alzheimer's Fund | Angel (individual) | Minority | 000 0000 | 000000 0 |
Amylyx Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Joshua Cohen | Co-Founder, Chief Executive Officer and Board Member | ||
| Justin Klee | Co-Founder, President and Board Member | ||
| Kent Leslie | Vice President of Research |
Amylyx Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Alan Walts Ph.D | Self | Board Observer | 000 0000 | |
| Felix von Coerper | ALS Investment Fund | Board Member | 000 0000 | |
| George Milne | Amylyx | Board Member | 000 0000 | |
| Henri Termeer Ph.D | Self | Board Observer & Advisor | 000 0000 | |
| Isaac Cheng MD | Morningside Group | Board Member | 000 0000 |